Recurrent and chronic central serous chorioretinopathy. Retina thickness evaluation one month after intravitreal bevacizumab injection

Gregori-Gisbert, I.; Aguirre-Balsalobre, F.; García–Sánchez, J.; León-Salvatierra, G.; Mengual-Verdú, E.; Hueso-Abancens, J.R.

doi:10.1016/j.oftale.2011.05.007

Cited by 3 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intravitreal use of bevacizumab for chronic CSC was first reported by Niegel et al (22). Since then, several studies have been reported and the results suggest that intravitreal use of bevacizumab is safe and effective for the treatment of chronic CSC (10)(11)(12)(13). In the current study, BCVA improved in 4 of 6 cases at the end of follow-up, after IVB injection (p˃0.05).…”

Section: Discussionmentioning

confidence: 99%

“…Bevacizumab (Avastin, Genentech), an antibody to vascular endothelial growth factor (VEGF), is known to have antipermeability effects and therefore it may target the pathophysiology of CSC theoretically. Both anatomical and functional improvements following intravitreal bevacizumab (IVB) injection in patients with chronic CSC have been reported in case series (10)(11)(12)(13). In this study, we aimed to compare the anatomical and functional outcomes of PDT versus IVB injection in the treatment of chronic CSC.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of Photodynamic Therapy Versus Intravitreal Bevacizumab Injection for Chronic Central Serous Chorioretinopathy

Tufan¹,

Ünlü²,

Arıkan³

et al. 2014

Turk J Bioch

View full text Add to dashboard Cite

Amaç: Kronik santral seröz koryoretinopati (SSR) tedavisinde fotodinamik tedavi (PDT) ile intravitreal bevacizumab'ın (IVB) etkinliğini karşılaştırmak. Yöntem: Semptomatik kronik SSR nedeniyle PDT (n=9) veya IVB (n=6) uygulanmış 15 hastanın 16 gözüne ait dosyalar retrospektif olarak incelendi. İki grup, en iyi düzeltilmiş görme keskinliği (EDGK), santral makülar kalınlık (SMK) ve subretinal sıvı (SRS) volümü açısından tedavi sonrası 1., 3. ve 6. aylarda karşılaştırıldı. Bulgular: Tüm zaman dilimlerinde, ortanca EDGK açısından her iki grup benzerdi (p>0.05). SMK azalması açısından 1. ve 3. aylarda iki grup arasında anlamlı fark izlenirken (p<0.05), 6. ayda bu fark anlamlı değildi (p˃0.05). SRS rezorpsiyonu 1. ve 3. aylarda PDT grubunda anlamlı olarak daha iyi iken 6. ayda bu fark anlamlı değildi (p˃0.05). Sonuç: Hem PDT hem de IVB enjeksiyonu kronik CSC'de görsel ve anatomik düzelme sağlamaktadır. Ancak PDT, tedavi sonrası üç aylık dönemde SMK'de ve SRS'de düzelme açısından IVB'den üstün görünmekterdir. Objective:To compare the efficacy of photodynamic therapy (PDT) versus intravitreal bevacizumab (IVB) injection for the treatment of chronic central serous chorioretinopathy (CSC). Method: The medical records of 16 eyes of 15 patients who received PDT (n=9) or IVB (n=6) for symptomatic chronic central serous chorioretinopathy (CSC) were retrospectively reviewed. Best-corrected visual acuity (BCVA), central macular thickness (CMT), and subretinal fluid (SRF) volume were compared between the two patient groups at baseline and at 1,3 and 6 months after treatment. Results: Median BCVA was similar in both groups at all time points (p>0.05). The reduction of CMT was significant at the 1st and 3rd month (p<0.05), however, it was non-significant at the 6th month among two groups (p˃0.05). SRF resorption was significantly better in the PDT group when compared to IVB group at the 1st and 3rd month (p<0.05), while it was nonsignificant at the 6th month (p˃0.05). Conclusion: Both PDT and IVB injection provided visual and anatomical recovery for chronic CSC. However, PDT appeared superior to IVB in terms of improving CMT and SRF throughout three months after treatment.Anahtar Kelimeler: Kronik santral seröz koryoretinopati, fotodinamik tedavi, intravitreal bevacizumab.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Efficacy of Photodynamic Therapy Versus Intravitreal Bevacizumab Injection for Chronic Central Serous Chorioretinopathy

Tufan¹,

Ünlü²,

Arıkan³

et al. 2014

Turk J Bioch

View full text Add to dashboard Cite

show abstract

Comparison of Therapeutic Effect Between Half-Energy Photodynamic Therapy and Intravitreal Bevacizumab Injection in Chronic Central Serous Chorioretinopathy for 12 Months

Kim

Lee

Kim

et al. 2013

J Korean Ophthalmol Soc

View full text Add to dashboard Cite

Journal of Experimental and Clinical Medicine

Cokluk¹

View full text Add to dashboard Cite

The aim of this study was to compare the efficacy and safety of latanoprost, travoprost and bimatoprost monotherapies in previously untreated patients with open angle glaucoma and ocular hypertension. This study included thirty-six eyes of 18 patients diagnosed with primary open angle glaucoma (POAG) and ocular hypertension (OHT) at Ondokuz Mayıs University, Medical Faculty, Department of Ophthalmology. All patients were underwent complete ophthalmic examination. Patients were randomized into 3 groups with six patients; group 1 received latanoprost 0.005% (Xalatan, Pharmacia), group 2 received travoprost 0.004% (Travatan, Alcon) and group 3 received bimatoprost 0.03% (Lumigan, Allergan) monotherapies. First examination was performed at the beginning of the study. Control examinations were performed at the 2, 4, 12 and 24th weeks of the therapy. Efficacy and side effects of these drugs were evaluated on each control visits. There were no significant differences in demographic characteristics among treatment groups. Baseline mean intra ocular pressure (IOP) levels were 26.50±3.14 mmHg in group 1, 25.58±3.62 mmHg in group 2 and 24.66±3.62 mmHg in group 3. Mean IOP levels were similar at end of the study between groups and 14.83±2.24 mmHg in group 1, 16.41±4.16 mmHg in group 2 and 16.16±3.53 mmHg in group 3. The most frequent side-effect was conjunctival hyperemia, which was determined in none of the patients in group 1, in 2 eyes in group 2 (16.7%) and 6 eyes in group 3 (50%). There was no statistically significant difference of IOP between latanoprost, travoprost and bimatoprost monotherapies. The side-effects were fewest in the latanoprost group and the most frequent in the bimatoprost group.

show abstract

Recurrent and chronic central serous chorioretinopathy. Retina thickness evaluation one month after intravitreal bevacizumab injection

Cited by 3 publications

References 5 publications

Efficacy of Photodynamic Therapy Versus Intravitreal Bevacizumab Injection for Chronic Central Serous Chorioretinopathy

Efficacy of Photodynamic Therapy Versus Intravitreal Bevacizumab Injection for Chronic Central Serous Chorioretinopathy

Comparison of Therapeutic Effect Between Half-Energy Photodynamic Therapy and Intravitreal Bevacizumab Injection in Chronic Central Serous Chorioretinopathy for 12 Months

Journal of Experimental and Clinical Medicine

Contact Info

Product

Resources

About